Galecto

Galecto, Inc. develops small molecules for the treatment of serious diseases, including fibrosis and cancer. Founded in 2011, the company has conducted more than a decade of research based on the role of galectin-3 and LOXL-2, as well as the application of modulators of these proteins in the treatment of fibrosis-related diseases and cancer. Combined with a strong patent portfolio, these assets provide Galecto with a unique therapeutic platform.